Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens.

Estrogen increases the ability of the estrogen-dependent MCF-7 human breast cancer cell line to both proliferate and invade through an artificial basement membrane. In studying the response of MCF-7 cells to various antiestrogens, we found that 4-hydroxytamoxifen and tamoxifen inhibited cell proliferation but increased their invasiveness. In contrast, the structurally unrelated benzothiophene antiestrogens, LY117018 and LY156758, were potent antiproliferative agents which did not stimulate invasiveness. The differential effects of these antiestrogenic agents on invasion correlated with changes in production of collagenase IV, while no significant change was seen in the chemotactic activity of the cells. Invasiveness was increased by 17 beta-estradiol or 4-hydroxytamoxifen after a few hours of treatment and was rapidly lost when 17 beta-estradiol was withdrawn. Stimulation of invasiveness with 17 beta-estradiol was blocked by the antiestrogen, LY117018. Cells from the MDA-MB-231 line which lacks estrogen receptors were not affected by estrogen or antiestrogen in terms of proliferation or invasion. These studies indicate that the invasiveness of MCF-7 cells is regulated by antiestrogens through the estrogen receptor and may be mediated by collagenase IV activity. Antiestrogens which reduce both the proliferation and invasiveness of these cells may be interesting new candidates for clinical application.

[1]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[2]  Y. Iwamoto,et al.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. , 1988, Cancer research.

[3]  F. May,et al.  Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells. , 1987, The Journal of biological chemistry.

[4]  T. Powles,et al.  TAMOXIFEN AND BENIGN BREAST PROBLEMS , 1987, The Lancet.

[5]  M. Lippman,et al.  Effect of v-rasH oncogene transfection on estrogen-independent tumorigenicity of estrogen-dependent human breast cancer cells. , 1987, Cancer research.

[6]  B. Katzenellenbogen,et al.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.

[7]  V. Jordan,et al.  Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. , 1987, Cancer research.

[8]  C. Osborne,et al.  Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. , 1987, European journal of cancer & clinical oncology.

[9]  V. Jordan,et al.  Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. , 1987, Cancer research.

[10]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[11]  R. Dickson,et al.  Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. , 1987, Endocrine reviews.

[12]  V. Jordan,et al.  Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. , 1987, Cancer research.

[13]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[14]  H. Kleinman,et al.  17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Sutherland,et al.  Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. , 1986, Biochemical and biophysical research communications.

[16]  A. Sapino,et al.  Estrogen- and tamoxifen-induced rearrangement of cytoskeletal and adhesion structures in breast cancer MCF-7 cells. , 1986, Cancer research.

[17]  B. Katzenellenbogen,et al.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Stern,et al.  Collagenases in human breast carcinoma cell lines. , 1986, Cancer research.

[19]  L. Liotta,et al.  Laminin increases the release of type IV collagenase from malignant cells. , 1986, The Journal of biological chemistry.

[20]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[21]  B. Katzenellenbogen,et al.  An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor. , 1985, Endocrinology.

[22]  V. Jordan,et al.  Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. , 1985, Biochemical pharmacology.

[23]  C. Sonnenschein,et al.  Estrogenic effect of tamoxifen and its derivatives on the proliferation of MCF7 human breast tumor cells. , 1985, Life sciences.

[24]  D. Lowy,et al.  Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. , 1985, Science.

[25]  M. Lippman,et al.  Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. , 1985, Cancer research.

[26]  C. Osborne,et al.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. , 1985, Cancer research.

[27]  R. Sutherland,et al.  Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. , 1984, European journal of cancer & clinical oncology.

[28]  A. Krust,et al.  Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. , 1984, The Journal of biological chemistry.

[29]  M. Lippman,et al.  Hormonal control of plasminogen activator secretion in ZR-75-1 human breast cancer cells in culture. , 1984, Endocrinology.

[30]  L. Liotta,et al.  Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. , 1982, Biochemistry.

[31]  B. Katzenellenbogen,et al.  Uterine plasminogen activator activity: modulation by steroid hormones. , 1982, Endocrinology.

[32]  L. Black,et al.  Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. , 1981, Endocrinology.

[33]  C. Redmond,et al.  Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.

[34]  V. Jordan,et al.  Geometric isomers of substituted triphenylethylenes and antiestrogen action. , 1981, Endocrinology.

[35]  L. Murphy,et al.  High-affinity anti-oestrogen binding site distinct from the oestrogen receptor , 1980, Nature.

[36]  H. Soule,et al.  Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. , 1980, Cancer letters.

[37]  V. Jordan,et al.  Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosis. , 1980, The Journal of endocrinology.

[38]  L. Black,et al.  Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. , 1980, Life sciences.

[39]  L. Liotta,et al.  Activation of human breast carcinoma collagenase through plasminogen activator. , 1980, Life sciences.

[40]  P. Band,et al.  Tamoxifen-induced tumor stimulation and withdrawal response. , 1979, Cancer treatment reports.

[41]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. , 1978, The Journal of biological chemistry.

[42]  S. Saez,et al.  Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. , 1978, The Journal of endocrinology.

[43]  V. Jordan,et al.  Effect of non-steroidal anti-oestrogens on the concentration of rat uterine progesterone receptors. , 1978, The Journal of endocrinology.

[44]  W. McGuire,et al.  Progesterone interaction with estrogen and antiestrogen in the rat uterus — receptor effects , 1977, Steroids.

[45]  T. Allen,et al.  REGULATION OF PROGESTERONE RECEPTOR FORMATION BY ESTROGEN ACTION * , 1977, Annals of the New York Academy of Sciences.

[46]  M. Lippman,et al.  The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.

[47]  M. Lippman,et al.  Model systems for the study of estrogen action in tissue culture. , 1976, Journal of steroid biochemistry.

[48]  R. Simon,et al.  Evaluation of tamoxifen dose in advanced breast cancer: a progress report. , 1976, Cancer treatment reports.

[49]  J. Heuson Current overview of EORTC clinical trials with tamoxifen. , 1976, Cancer treatment reports.

[50]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[51]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[52]  J. Firmat,et al.  [Endocrine therapy of metastatic breast cancer]. , 1958, Revista argentina de endocrinologia y metabolismo.

[53]  S. Robinson,et al.  Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. , 1988, Journal of steroid biochemistry.

[54]  V. Jordan,et al.  Strategies for breast cancer therapy with antiestrogens. , 1987, Journal of steroid biochemistry.

[55]  I. Hindy,et al.  Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. , 1986, Oncology.

[56]  L. Liotta,et al.  Cancer cells, components of basement membranes, and proteolytic enzymes. , 1985, International review of experimental pathology.

[57]  B. Katzenellenbogen,et al.  Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. , 1984, Cancer research.

[58]  L. Green,et al.  Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. , 1984, Journal of steroid biochemistry.

[59]  W. Borth,et al.  Influence of plasma fibronectin on collagen cleavage by collagenase. , 1983, Collagen and related research.

[60]  W. McGuire,et al.  Antiestrogens: Mechanism of Action and Effects in Breast Cancer , 1978 .